Leonard R Krilov Selected Research

Palivizumab

3/2021	Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States.
1/2020	Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
3/2018	Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.
9/2015	Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants.
10/2014	Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
1/2011	Respiratory syncytial virus disease: update on treatment and prevention.
10/2002	Palivizumab in the prevention of respiratory syncytial virus disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leonard R Krilov Research Topics

Disease

6	Respiratory Syncytial Virus Infections 03/2021 - 01/2011
3	Congenital Heart Defects (Congenital Heart Defect) 03/2021 - 10/2002
3	Respiratory Tract Infections (Respiratory Tract Infection) 12/2018 - 01/2006
2	Communicable Diseases (Infectious Diseases) 03/2021 - 09/2015
2	Lung Diseases (Lung Disease) 03/2021 - 10/2014
2	Infections 07/2018 - 01/2006
2	Human Influenza (Influenza) 07/2012 - 01/2006
1	Paramyxoviridae Infections (Parainfluenza) 01/2020
1	Glomerulonephritis 07/2018
1	Bacterial Infections (Bacterial Infection) 08/2015
1	Bronchitis 08/2015
1	Cough 08/2015
1	Asthma (Bronchial Asthma) 08/2015
1	Tuberculosis (Tuberculoses) 01/2006
1	Intraabdominal Infections 01/2006
1	Pneumonia (Pneumonitis) 01/2006
1	Sinusitis 01/2006
1	Cystic Fibrosis (Mucoviscidosis) 10/2002

Drug/Important Bio-Agent (IBA)

7	Palivizumab FDA Link 03/2021 - 10/2002
1	antiarrhythmic peptide (AAP)IBA 03/2021
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	Respiratory Syncytial Virus VaccinesIBA 12/2018
1	VaccinesIBA 12/2018
1	Complement System Proteins (Complement)IBA 07/2018
1	CreatinineIBA 07/2018
1	Immunoglobulin G (IgG)IBA 07/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 07/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2017
1	SteroidsIBA 08/2015
1	Influenza Vaccines (Influenza Vaccine)FDA Link 07/2012
1	Monoclonal AntibodiesIBA 01/2011
1	motavizumab (Numax)IBA 01/2011
1	Antiviral Agents (Antivirals)IBA 01/2011
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2011
1	Oseltamivir (Tamiflu)FDA Link 01/2006
1	Moxifloxacin (Avelox)FDA Link 01/2006
1	Gatifloxacin (Zymar)FDA Link 01/2006

Therapy/Procedure

2	Therapeutics 08/2015 - 10/2002
1	Aftercare (After-Treatment) 07/2018